Shingrix logo

Product menu

Middle-aged woman has blown out the candles on her 50th birthday cake, producing red smoke.
Recommend the shingles vaccine formulated to address age-related decline in immunity to varicella-zoster virus.1-4

SHINGRIX▼ demonstrated >90% efficacy against shingles in all age groups 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.1,2,5,6

UK SHINGRIX supply available now - ORDER SHINGRIX HERE

UK Packshot of SHINGRIX showing the box (orange and white) and two vials. The powder (antigen) vial (green and brown cap) and the suspension (adjuvant) vial (turquoise and red cap).

What is SHINGRIX?

SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:

  • adults 50 years of age or older;
  • adults 18 years of age or older at increased risk of HZ.1,2

Use of SHINGRIX should be in accordance with official recommendations.1,2

SHINGRIX is contraindicated in anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.1,2

Learn more about how SHINGRIX works

SHINGRIX is specifically formulated to address the age-related decline in shingles immunity.1-4

SHINGRIX reconstitution instructions

Instructions for reconstituting and administering SHINGRIX to your patients 50 years of age and older.1,2

SPEAK TO A MEMBER OF OUR TEAM

Prescribing information (GB)

Download

Prescribing information (NI)

Download

Summary of product characteristics & Patient information leaflet (GB)

open

Summary of product characteristics & Patient information leaflet (NI)

open

Learn more about SHINGRIX

Red virus icon

Addressing age-related decline in immunity.

SHINGRIX – specifically formulated to help address age-related decline in varicella zoster virus specific immunity in adults 50 years of age and older.1-4

UNDERSTAND THE SCIENTIFIC RATIONALE

Red patient icon, 4 patient figures, 1 of the 4 coloured grey

Who can benefit from SHINGRIX?

There is a 1 in 4 lifetime risk of developing shingles.7 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.8,9

View Patient Profiles

Red circular icon, showing greater than 90% efficacy against herpes zoster

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90 % efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.1,2,5,6

Review Efficacy Data

References

  1. Shingrix, GB Summary of Product Characteristics (SPC)
  2. Shingrix, NI Summary of Product Characteristics (SPC)
  3. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella- zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32 (15):1745-53.
  4. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8):1280-90.
  5. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  6. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  7. DH Green Book ch 28a - Shingles. February 2016. Accessed July 2021.
  8. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009 137 38-472.
  9. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  10. Crooke, S.N., et al.Immun Ageing. 2019 Sep 13; 16:25.
  11. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012 Apr;30 (20): 3126-35.
  12. Public Health England Green Book. Immunisation Procedures Chapter 4. Jun 2012.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

PM-GB-SGX-WCNT-210006
Date of preparation: July 2021
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.